NCT00294190View on ClinicalTrials.gov

Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

September 30, 2007

Study Completion Date

July 31, 2009

Conditions
Small Cell Lung CancerCarcinoma, Small Cell
Interventions
DRUG

Topotecan

Topotecan 6mg/m2 IV weekly x 6 consecutive weeks followed by a 2 week break.

Trial Locations (13)

29303

Spartanburg Regional Medical Center, Spartanburg

30501

Northeast Georgia Medical Center, Gainesville

32804

Florida Hospital Cancer Institute, Orlando

33805

Watson Clinic Center for Cancer Care and Research, Lakeland

33901

Florida Cancer Specialists, Fort Myers

37023

Tennessee Oncology, PLLC, Nashville

37404

Chattanooga Oncology Hematology Associates, Chattanooga

40207

Consultants in Blood Disorders and Cancer, Louisville

45242

Oncology Hematology Care, Cincinnati

49503

Grand Rapids Clinical Oncology Program, Grand Rapids

68114

Methodist Cancer Center, Omaha

71301

Hematology Oncology Life Center, Alexandria

72401

Northeast Arkansas Clinic, Jonesboro

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER

NCT00294190 - Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer | Biotech Hunter | Biotech Hunter